{"id":"NCT01195831","sponsor":"LEO Pharma","briefTitle":"Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis","officialTitle":"Multicentre, Randomized, Investigator-Blinded, Parallel-group Study to Assess the Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2010-09-06","resultsPosted":"2012-04-19","lastUpdate":"2025-03-12"},"enrollment":244,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Scalp Psoriasis"],"interventions":[{"type":"DRUG","name":"Xamiol® gel","otherNames":[]},{"type":"DRUG","name":"Calcipotriol scalp solution","otherNames":[]}],"arms":[{"label":"Xamiol® gel","type":"EXPERIMENTAL"},{"label":"Calcipotriol scalp solution","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the clinical efficacy of once daily treatment for 4 weeks with Xamiol® gel (calcipotriol plus betamethasone) with twice daily treatment for 4 weeks with Calcipotriol Scalp Solution in patients with scalp psoriasis.","primaryOutcome":{"measure":"Patients With \"Controlled Disease\" in Terms of \"Clear\" or \"Minimal\" According to Investigator's Global Assessment of Disease Severity at Week 4.","timeFrame":"4 weeks","effectByArm":[{"arm":"Xamiol® Gel","deltaMin":87.5,"sd":null},{"arm":"Calcipotriol Scalp Solution","deltaMin":50.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":9,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://www.leopharmatrials.com/en"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":118},"commonTop":["Upper respiratory tract infection","Application site pain","Application site warmth"]}}